Trials / Completed
CompletedNCT06102005
Dose Ranging Study of Lunsekimig Compared With Placebo-control in Adult Participants With Moderate-to-severe Asthma
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Lunsekimig in Adult Participants With Moderate-to-severe Asthma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 685 (actual)
- Sponsor
- Sanofi · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 2b, global, multicenter, randomized, double-blind, placebo-controlled, parallel group, dose ranging study to assess the efficacy, safety, and tolerability of add-on therapy with SC lunsekimig in adult participants aged 18 to 80 years, (inclusive) with moderate-to-severe asthma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lunsekimig | Pharmaceutical form: solution for injection Route of administration: subcutaneous |
| DRUG | Placebo | Pharmaceutical form: solution for injection Route of administration: subcutaneous |
Timeline
- Start date
- 2023-10-16
- Primary completion
- 2026-02-23
- Completion
- 2026-03-11
- First posted
- 2023-10-26
- Last updated
- 2026-03-17
Locations
156 sites across 14 countries: United States, Argentina, Brazil, Canada, Chile, China, India, Israel, Japan, Mexico, South Africa, South Korea, Turkey (Türkiye), United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06102005. Inclusion in this directory is not an endorsement.